Psoriasis is a multifactorial disease influenced significantly by genetics and environmental factors that trigger complex biological processes including immune response dysregulation and cytokine production. The IL-23/Th17 axis, particularly the role of IL-17, has been identified as critical in the development of psoriatic lesions. This understanding has led to the creation of targeted biologic therapies, specifically anti-IL17 and anti-IL23 monoclonal antibodies. These therapies, which include drugs like secukinumab, ixekizumab, and guselkumab, have been successful in clinical trials and real-world applications, often achieving complete or near-complete clearance of psoriatic lesions. Moreover, these biologics are generally well tolerated with a favorable safety profile, although there are nuances in their long-term effects and specific adverse events such as Candida infections associated with IL-17 inhibitors. The effectiveness of these drugs underscores the pivotal role of the IL-23/Th17 axis in psoriasis pathogenesis and highlights the potential for further personalized medical approaches in treating psoriasis.

Reference: Potestio L, Martora F, Lauletta G, Vallone Y, Battista T, Megna M. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. Clin Cosmet Investig Dermatol. 2024 Apr 10;17:829-842. doi: 10.2147/CCID.S462797. PMID: 38616886; PMCID: PMC11016251.